# BrightInsight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brightinsight

- Industry: Healthcare IT
- Headquarters: San Jose, US
- Website: www.brightinsight.com
- Total disclosed funding: $173M
- Latest round: Series C (Mar 10, 2021)
- Investors on record: 6

## About

BrightInsight, Inc. is a US-based company specializing in digital health solutions, particularly in the development and management of Software as a Medical Device (SaMD) applications to enhance patient engagement.Founded in 2017, BrightInsight, Inc. operates from San Jose, US, providing digital health solutions. The company has engaged in three funding rounds, with the most recent being a Series C round in March 2021, raising USD 108 mn, led by General Catalyst Partners, and includes contributions from other investors like Alpha Partners and Gaingels. The firm has a current valuation of USD 626.72 mn, and its founders are Ferry Tamtoro and Kal Patel, with Kal Patel serving as CEO.BrightInsight's primary offering is the BrightInsight Platform, a comprehensive digital health solution for developing and managing Software as a Medical Device (SaMD) applications. The platform supports various digital health initiatives for life sciences companies, enhancing patient engagement and providing data-driven insights in areas such as oncology and cardiovascular diseases. Notable products, like the Hizentra app, demonstrate the platform's effectiveness and are marketed primarily in North America and Europe.BrightInsight generates revenue through long-term partnerships with biopharma companies that utilize the BrightInsight Platform. The company adopts a subscription-based pricing model, enabling clients to access platform features and updates. This B2B approach emphasizes collaboration and tailored solutions for digital health strategies. In January 2026, BrightInsight, Inc. raised USD 13 million in venture funding from investors Eclipse Ventures, General Catalyst Partners, Insight Partners, New Leaf Venture Partners and Mayo Clinic Ventures.  The company will use the funding to advance its AI-based medication adherence tools and expand its programs worldwide.

## Funding rounds

- Series C, Mar 10, 2021, $108M — General Catalyst Partners, Insight Partners, New Leaf Venture Partners, Alpha Partners, Eclipse Ventures, Gaingels
- Series B, Jun 10, 2020, $40M — Insight Partners, New Leaf Venture Partners, Eclipse Ventures
- Series A, Aug 1, 2019, $25M — New Leaf Venture Partners, Eclipse Ventures

## Investors

- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series A, Series B, Series C
- Eclipse Ventures (https://capitalatlas.ai/funds/eclipse-ventures) — Series A, Series B, Series C
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series B, Series C
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series C
- Alpha Partners (https://capitalatlas.ai/funds/alpha-partners) — Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series C